3 results match your criteria: "Bernstein Clinical Research Center and University of Cincinnati[Affiliation]"
Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
J Allergy Clin Immunol Pract
October 2020
Bernstein Clinical Research Center and University of Cincinnati, Cincinnati, Ohio.
Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
J Allergy Clin Immunol
December 2016
Merck & Co, Kenilworth, NJ.
Background: The house dust mite (HDM) sublingual immunotherapy (SLIT) tablet (MK-8237; Merck & Co, Kenilworth, NJ/ALK-Abelló, Hørsholm, Denmark) has demonstrated beneficial effects on allergic rhinoconjunctivitis and asthma outcomes in European trials.
Objective: This is the first trial to assess the efficacy/safety of HDM SLIT-tablets in North American subjects with HDM-induced allergic rhinitis with or without conjunctivitis (AR/C).
Methods: In this double-blind, multicenter trial (NCT01700192) 1482 subjects (aged ≥12 years) with HDM-induced AR/C with or without asthma were randomized to a daily SQ HDM SLIT-tablet (12 SQ-HDM dose) or placebo for up to approximately 52 weeks.
Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.
Ann Allergy Asthma Immunol
February 2014
Merck & Co, Inc, Whitehouse Station, New Jersey.
Background: In North America, few studies have evaluated sublingual immunotherapy for allergic rhinitis with or without conjunctivitis (AR/C); pediatric data are sparse. The authors report findings from the largest published immunotherapy trial yet conducted in adults and children.
Objective: To evaluate grass sublingual immunotherapy tablet (MK-7243) treatment in subjects with AR/C.